Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece

Table 6

Chemotherapy regimens that were administered as second-line treatment.

Second-line chemotherapy regimen	N	%
Nab-paclitaxel/gemcitabine	36	32.1
FOLFIRINOX	27	24.1
CAPOXIRI	1	0.9
FOLFOX	18	16.1
CAPOX	4	3.6
Gemcitabine	6	5.4
Capecitabine	2	1.8
FOLFIRI	6	5.4
Gemcitabine/oxaliplatin	6	5.4
Gemcitabine/capecitabine	2	1.8
Cisplatin/gemcitabine	1	0.9
Cisplatin/irinotecan	1	0.9
Nab-paclitaxel	2	1.8
Total	112	100.0

CAPOX, oxaliplatin/capecitabine; CAPOXIRI, oxaliplatin/irinotecan/capecitabine; FOLFIRI, irinotecan/leucovorin/5-fluorouracil; FOLFOX, oxaliplatin/leucovorin/5-fluorouracil; FOLFIRINOX, oxaliplatin/irinotecan/leucovorin/5-fluorouracil.